Eli Lilly reaches deal to bring AI-developed drugs to global market
Eli Lilly reaches deal to bring AI-developed drugs to global market
Publish Date: 2026-03-29 09:36:00
Source Domain: www.cnbc.com
- Significant Pharmaceutical Collaboration: Eli Lilly, a U.S. pharmaceutical giant, has agreed to a $2.75 billion deal to bring novel drugs from Hong Kong-based Insilico Medicine to the global market.
- AI-Driven Drug Development: Insilico utilizes generative AI to develop drugs, with at least 28 drugs, nearly half of which are already at a clinical stage.
- Initial Investment and Future Earnings: The agreement includes an upfront payment of $115 million to Insilico, with the rest contingent on regulatory and commercial milestones, as well as future sales royalties.
- Lilly’s Strategic AI Integration: Eli Lilly’s collaboration with Insilico leverages Insilico’s AI-driven discoveries to complement Lilly’s clinical development strengths, aiming to accelerate the identification of promising therapeutic candidates.
- Global Drug Research Operations: While Insilico’s AI R&D happens in Canada and the Middle East, it conducts early preclinical research in China, taking advantage of AI to synthesize molecules more quickly.
- Lilly’s Asia Investments: Eli Lilly is also planning to invest $3 billion in China within the next decade, with a slight increase in its revenue from China anticipated despite the country still accounting for less than 3% of its overall revenue.
